Valbiotis SA

Paris Stock Exchange ALVAL.PA

Valbiotis SA Free Cash Flow Per Share for the year ending December 31, 2023: USD -0.74

Valbiotis SA Free Cash Flow Per Share is USD -0.74 for the year ending December 31, 2023, a 26.52% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.
  • Valbiotis SA Free Cash Flow Per Share for the year ending December 31, 2022 was USD -1.00, a -6.47% change year over year.
  • Valbiotis SA Free Cash Flow Per Share for the year ending December 31, 2021 was USD -0.94, a -343.28% change year over year.
  • Valbiotis SA Free Cash Flow Per Share for the year ending December 31, 2020 was USD 0.39, a 130.96% change year over year.
  • Valbiotis SA Free Cash Flow Per Share for the year ending December 31, 2019 was USD -1.25, a 20.27% change year over year.
Key data
Date Free Cash Flow Per Share Return on Assets (ROA) Return on Equity (ROE) Return on Capital Employed (ROCE)
Market news
SV Wall Street
Paris Stock Exchange: ALVAL.PA

Valbiotis SA

CEO Mr. Sebastien Peltier HDR, Ph.D.
IPO Date June 7, 2017
Location France
Headquarters rue Paul Vatine
Employees 52
Sector Health Care
Industries
Pharmaceuticals Biotechnology Clinical Trials Research & Consulting
Description

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.

Similar companies

OSE.PA

OSE Immunotherapeutics SA

USD 6.91

1.86%

StockViz Staff

January 31, 2025

Any question? Send us an email